生物技術、藥物開發和藥物輸送系統中的納米顆粒

生物技術、藥物開發和藥物輸送系統中納米粒子的全球市場規模預計將從 2023 年的 1027 億美元增長，2023 年至 2028 年的預測期內復合年增長率為 8.8%，達到 2028 年。 2018年增長至1568億美元。

預計到 2028 年，給藥系統行業將從 2023 年的 538 億美元增長到 751 億美元，複合年增長率為 6.9%。 診斷行業預計將從 2023 年的 24 億美元增長到 2028 年的 42 億美元，複合年增長率為 11.8%。

本報告探討了生物技術、藥物開發和藥物輸送系統中納米顆粒的全球市場，提供了市場和產品概述、市場影響因素和市場機會分析、監管環境和市場規模趨勢。□預測、詳細分析按類別/地區、技術/專利趨勢、競爭格局、主要公司概況等

內容

第 1 章簡介

第 2 章摘要要點

第 3 章市場概述

• 納米粒子：概述
• 脂質體
• 量子點
• 樹枝狀聚合物
• 聚合物納米顆粒
• 納米粒子的歷史：概述
• 納米粒子在生物技術中的應用
• 藥物開發中的納米顆粒
• 藥物輸送系統中的納米顆粒
• 診斷成像中的納米顆粒
• 納米顆粒藥物輸送領域的主要參與者
• 主要納米粒子和納米晶藥物
• 市場動態
• 促進因素
• 抑制因素
• PESTEL 分析
• 監管狀況
• 納米粒子最新技術

第 4 章納米技術在 COVID-19 疫苗製造中的作用

• 抗擊新型冠狀病毒
• COVID-19 的結構和傳染性
• COVID-19 疫苗面臨的挑戰
• 疫苗設計的組成部分和方法
• 抗原
• 佐劑
• 納米顆粒和納米載體
• 設備
• 納米技術的進步使下一代疫苗成為可能
• 概述：利用納米技術治療新冠肺炎 (COVID-19)

第 5 章全球生物技術、藥物開發和藥物輸送系統中的納米顆粒市場：按技術分類

• 技術概述
• 脂質體
• 聚合物膠束
• 樹枝狀聚合物
• 其他

第 6 章生物技術、藥物開發和藥物輸送系統領域的全球納米顆粒市場：按應用分類

• 生物技術
• 藥物開發和配方
• 藥物輸送系統
• 影像診斷

第 7 章納米顆粒結構

• 納米顆粒在應用市場中的採用
• 液晶顯示屏
• 液體載體
• 脂質體
• 樹枝狀聚合物
• 殼聚醣海藻酸鹽
• 納米晶體
• 量子點
• 納米粒子在藥物遞送中的應用

第 8 章納米粒子製造

• 納米顆粒形成方法
• 自組織
• 穩定
• 引入藥物的方法
• 聚合物納米粒子
• 膠束
• 脂質體
• 金和矽納米顆粒
• 樹枝狀聚合物
• 如何將生物分子負載到納米顆粒上
• 納米藥物
• 大規模納米粒子生產的問題

第 9 章生物技術中的納米粒子

• 研究與開發
• 幹細胞研究
• 細胞修復
• 順磁性和超順磁性納米粒子
• 生物傳感器和量子點
• 納米顆粒研究合作項目

第 10 章藥物開發和製劑中的納米顆粒

• 生物分離
• 快速藥物分析
• 去除雜質和毒素
• 使用納米粒子摻入不溶性藥物
• 生物醫學中的金銀納米粒子
• 開髮用於 DNA 特異性藥物的 DNA 納米顆粒

第 11 章藥物輸送系統中的納米顆粒

• 納米粒子在藥物輸送應用中的應用
• 納米粒子給藥系統的設計
• 納米顆粒藥物的穩定性
• 納米顆粒製劑的尺寸均勻性
• 納米顆粒的載藥量
• 納米顆粒的藥物釋放
• 納米顆粒藥物釋放的外部觸發因素
• 將生物分子偶聯並納入納米顆粒中
• 納米顆粒的毒性
• 大規模製造
• 納米顆粒藥物的給藥方法
• 口服給藥
• 注射給藥
• 透皮貼劑
• 種植管理
• 吸入給藥
• 適用於藥物輸送系統的納米顆粒
• 脂質納米粒子
• 膠束納米顆粒
• 樹枝狀納米粒子
• 聚合物納米顆粒
• 金屬納米顆粒
• 生物聚合物納米顆粒
• 納米晶體
• 可提供納米顆粒藥物輸送系統
• 抗生素納米顆粒
• 抗腫瘤和通過納米顆粒遞送小分子
• 從納米顆粒中釋放抗癌藥物
• 通過納米粒子傳遞的生物大分子
• 用於藥物輸送系統的納米顆粒塗層
• 從體內去除納米顆粒

第 12 章體外和體內成像

• 體外成像
• 診斷成像中的納米顆粒

第 13 章全球生物技術、藥物開發和藥物輸送系統中的納米顆粒市場：按地區劃分

• 市場概覽/討論
• 北美
• 歐洲
• 亞太地區
• 其他地區
• 南美洲
• 中東和非洲

第 14 章競爭格局

• 納米顆粒藥物輸送系統和產品
• 納米顆粒藥物輸送系統的主要參與者
• 公司納米顆粒藥物輸送管道
• 納米粒子產品和營銷：驅動因素
• 納米粒子產品開發和營銷的限制

第 15 章專利、許可、併購

• 近期許可活動/併購
• 最近交易
• 納米粒子專利

第 16 章公司簡介

• BRISTOL-MYERS SQUIBB CO.
• CAMURUS AB
• CERAMISPHERE HEALTH PTY LTD.
• CYTIMMUNE SCIENCES
• GILEAD SCIENCES INC.
• GLAXOSMITHKLINE PLC
• HOFFMANN-LA ROCHE INC.
• MERCK & CO. INC.
• NANOCARRIER CO., LTD.
• NOVARTIS AG

Highlights:

The global nanoparticles in biotechnology, drug development, and drug delivery systems market should reach $156.8 billion by 2028 from $102.7 billion in 2023 at a compound annual growth rate (CAGR) of 8.8% for the forecast period of 2023 to 2028.

Drug delivery systems segment of the global nanoparticles in biotechnology, drug development, and drug delivery systems market is expected to grow from $53.8 billion in 2023 to $75.1 billion in 2028 at a CAGR of 6.9% for the forecast period of 2023 to 2028.

Diagnostics segment of the global nanoparticles in biotechnology, drug development, and drug delivery systems market is expected to grow from $2.4 billion in 2023 to $4.2 billion in 2028 at a CAGR of 11.8% for the forecast period of 2023 to 2028.

Report Scope:

The scope of the report includes an overview of the global market for nanoparticles in biotechnology, drug development and formulation, drug delivery systems, and diagnostics as well as analyses of global market trends, using 2022 as the base year and forecasting market sizes for 2023 through 2028 with compound annual growth rate (CAGR) projections.

The report includes an analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.

Market figures are based on revenues at the manufacturer level and are projected in dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded markets for existing products, and other factors affecting the market.

The study is arranged to offer an overview of existing nanoparticle technology and drug markets; it is accompanied by nanoproduct, company, geography, and mechanism of action, with forecasts broken down and covered by geographic regions and countries. Patent and clinical trial information is reviewed for various candidate nanodrugs. The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed.

Figures are reported in U.S. dollars and each case reflects currency fluctuations within the performance of revenue change. Revenue figures do not account for variations in local currencies. All market share data presented is on a global basis unless specifically mentioned.

Regional analysis includes North America (U.S., Canada, Mexico), Europe (U.K., Germany, France, Spain, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the world (South America, and the Middle East and Africa).

Report Includes:

• 25 data tables and 40 additional tables
• An updated overview and in-depth analysis of the global markets for nanoparticles in biotechnology, drug development and drug delivery systems
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimation of the actual market size and revenue forecast for nanoparticles in biotechnology, drug development and drug delivery systems market, and corresponding market share analysis by technology, application and region
• Highlights of the drug development, formulation, and the development of new drug delivery systems and detailed product analyses within health and wellness subsegments
• In-depth information (facts and figures) concerning the major factors influencing the progress of the market (benefits and industry-specific challenges) with respect to specific growth trends, upcoming technologies, prospects, and contributions to the overall market
• Discussion on the role of nanotechnology in the COVID-19 vaccine production, mechanism of action, components and methods in vaccine design for COVID-19 and challenges for vaccine disruptions
• Review of the leading and emerging drug products for each nanoparticle type, clinical trial landscape for various candidate nanodrugs, status of approvals of drugs in each segment, and penetration of technologies and research initiatives within the ecosystem
• Updated information on patents and patent applications on nanoparticles in biotechnology, drug development and drug delivery systems, and related scientific publications
• Identification of the major stakeholders and analysis of the competitive landscape based on recent developments, financial performances, and segmental revenues
• Descriptive company profiles of the leading global players in the market, including Bristol-Myers Squibb Co., Camurus, GlaxoSmithKline PLC, Merck & Co. Inc. and Novartis AG

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• What's New in This Report?
• Scope of Report
• Methodology
• Market Estimate
• Information Sources
• Primary Research
• Secondary Research
• Geographic Breakdown
• Market Segmentation
• Analyst's Credentials
• BCC Custom Research
• Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

• Introduction to Nanoparticles
• Liposomes
• Quantum Dots
• Dendrimers
• Macromolecule Nanoparticles
• Brief History of Nanoparticles
• Nanoparticles in Biotechnology
• Nanoparticles in Drug Development
• Nanoparticles in Drug Delivery Systems
• Nanoparticles in Diagnostic Imaging
• Major Players in the Nanoparticle Drug Delivery Field
• Major Nanoparticle/Nanocrystal Drugs
• Market Dynamics
• Drivers
• Restraints
• PESTEL Analysis
• Regulatory Landscape
• U.S.
• Europe
• India
• Emerging Technologies in Nanoparticles
• Gadolinium-Neutron Capture Therapy (Gd-NCT) for Glioblastoma Multiforme (GBM) Treatment
• Ligand-tethered Lipid Nanoparticles for Targeted RNA Delivery to treat Liver Fibrosis

Chapter 4 Role of Nanotechnology in COVID-19 Vaccine Production

• Introduction
• Fight Against Novel Coronavirus
• Structure of COVID-19 and Penetration
• Challenges for COVID-19 Vaccines
• Components and Methods in the Design of Vaccines
• Antigen
• Adjuvant
• Nanoparticle/Nanocarrier
• Device
• Next-Generation Vaccines Enabled Through Advances in Nanotechnology
• Conclusion on Nanotechnology Use Against COVID-19

Chapter 5 Global Market for Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems by Technology

• Technology Overview
• Liposomes
• Polymeric Micelles
• Dendrimers
• Others

Chapter 6 Global Market for Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems by Application

• Biotechnology
• Drug Development and Formulation
• Drug Delivery Systems
• Diagnostic Imaging

Chapter 7 Structure of Nanoparticles

• Adoption of Nanoparticles in Applied Markets
• Liquid Crystals
• Liquid Carriers
• Liposomes
• Dendrimers
• Chitosan and Alginate
• Nanocrystals
• Quantum Dots
• Application of Nanoparticles to Drugs Delivered

Chapter 8 Production of Nanoparticles

• Methods of Nanoparticle Formation
• Self-Assembly Production
• Methods of Stabilization
• Methods of Drug Introduction
• Polymeric Nanoparticles
• Micelles
• Liposomes
• Gold and Silicon Nanoparticles
• Dendrimers
• Methods for Loading Biological Molecules into Nanoparticles
• Nanocrystal Drugs
• Problems with Large-Scale Nanoparticle Production

Chapter 9 Nanoparticles in Biotechnology

• Research and Development
• Stem Cell Research
• Cellular Repair
• Paramagnetic and Superparamagnetic Nanoparticles
• Biosensors and Quantum Dots
• Nanoparticle Research Collaborative Programs

Chapter 10 Nanoparticles in Drug Development and Formulation

• Bio Separations
• Rapid Drug Analysis
• Removal of Impurities and Toxins
• Using Nanoparticles to Incorporate Insoluble Drugs
• Gold and Silver Nanoparticles in Biomedicine
• DNA Nanoparticle Development of DNA-Specific Drugs

Chapter 11 Nanoparticles in Drug Delivery Systems

• Nanoparticles in Drug Delivery Applications
• Designing a Nanoparticle Drug Delivery System
• Nanoparticle Drug Stability
• Size Homogeneity of Nanoparticle Preparations
• Drug Loading of Nanoparticles
• Drug Release from Nanoparticles
• External Triggers for Releasing Drugs from Nanoparticles
• Binding/Incorporation of Biomolecules to Nanoparticles
• Nanoparticle Toxicity
• Large-Scale Manufacturing
• Methods of Administration of Nanoparticle Drugs
• Oral Administration
• Injection Administration
• Transdermal Patch
• Implantation Administration
• Inhalation Administration
• Nanoparticles Suitable for Drug Delivery Systems
• Lipid-Based Nanoparticles
• Micelle Nanoparticles
• Dendrimer Nanoparticles
• Polymeric Nanoparticles
• Metal-Based Nanoparticles
• Biological Macromolecule Nanoparticles
• Nanocrystals
• Nanoparticle Drug Delivery Systems Now Available
• Antibiotic Nanoparticles
• Anti-Tumor and Small Molecule Delivery by Nanoparticle
• Release of Anti-Cancer Drugs from Nanoparticles
• Biomacromolecules Delivered by Nanoparticles
• Nanoparticles Coating for Drug Delivery Systems
• Removal of Nanoparticles from the Body

Chapter 12 In Vitro and In Vivo Diagnostic Imaging

• In Vitro Imaging
• Nanoparticles in Diagnostic Imaging

Chapter 13 Global Market for Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems by Region

• Market Overview and Discussion
• North America
• Europe
• Asia-Pacific
• Rest of the World
• South America
• Middle East and Africa

Chapter 14 Competitive Landscape

• Nanoparticle Drug Delivery Systems and Products
• Major Players in Nanoparticle Drug Delivery Systems
• Company Pipelines for Nanoparticle Drug Delivery
• Drivers of Nanoparticle Products and Marketing
• Limiters of Nanoparticle Product Development and Marketing

Chapter 15 Patents, Licensing, Mergers and Acquisitions

• Recent Licensing Activity, Mergers, and Acquisition
• Recent Deals
• Nanoparticle Patents

Chapter 16 Company Profiles

• BRISTOL-MYERS SQUIBB CO.
• CAMURUS AB
• CERAMISPHERE HEALTH PTY LTD.
• CYTIMMUNE SCIENCES
• GILEAD SCIENCES INC.
• GLAXOSMITHKLINE PLC
• HOFFMANN-LA ROCHE INC.
• MERCK & CO. INC.
• NANOCARRIER CO., LTD.
• NOVARTIS AG

List of Tables

• Summary Table A : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Application, Through 2028
• Summary Table B : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Technology, Through 2028
• Table 1 : Description of Nanoparticles Used in Drug Delivery and Diagnostic Imaging
• Table 2 : Applications of Nanoparticles in Biotechnology
• Table 3 : Applications of Nanoparticles in Drug Development
• Table 4 : Applications of Nanoparticles in Drug Delivery Systems
• Table 5 : Nanoparticles Used in Drug Delivery Systems
• Table 6 : Nanoparticles Used for In Vivo Diagnostic Imaging
• Table 7 : Major Players in the Nanoparticle Drug Field
• Table 8 : Major Nanoparticle/Nanocrystal Drug, by Product and Company
• Table 9 : Description of Nanomaterial Properties and Associated Risks
• Table 10 : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Technology, Through 2028
• Table 11 : Global Market for Liposomes Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, Through 2028
• Table 12 : Patents Related to Polymeric Micelles and Their Drug Delivery Applications, 2022
• Table 13 : Global Market for Polymeric Micelles Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, Through 2028
• Table 14 : Global Market for Dendrimers Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, Through 2028
• Table 15 : Global Market for Other Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, Through 2028
• Table 16 : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Application, Through 2028
• Table 17 : Global Market for Nanoparticles in Biotechnology, by Region, Through 2028
• Table 18 : Global Market for Nanoparticles in Drug Development and Formulation, by Region, Through 2028
• Table 19 : Global Market for Nanoparticles in Drug Delivery Systems, by Region, Through 2028
• Table 20 : Global Market for Nanoparticles in Diagnostics, by Region, Through 2028
• Table 21 : Nanoparticles Structure and Properties
• Table 22 : Nanoparticles Systems Approved for Drug Delivery
• Table 23 : Sample of Drugs Delivered Through Liposome Nanotechnology
• Table 24 : Nanoparticles in Biotechnology Applications
• Table 25 : Nano Biosensor Technology Under Development
• Table 26 : ETPN Strategic Research and Innovation Agenda
• Table 27 : Nanoparticles in Drug Development Applications
• Table 28 : Monoclonal antibody (mAb) Drugs with Potential for Use in Nanoparticles Delivery Systems
• Table 29 : Solid Lipid Nanoparticles-Reformatted Drugs
• Table 30 : Nanoparticles in Drug Delivery Applications
• Table 31 : Standard Routes of Drug Administration
• Table 32 : Nanoparticle Transdermal Patch Products
• Table 33 : Type of Nanoparticles Supplied in Drug Delivery Systems
• Table 34 : Mechanism for Removal of Nanoparticles from the Body
• Table 35 : Nanoparticles Contrast Media Used for In Vivo Diagnostic Imaging
• Table 36 : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery, by Region, Through 2028
• Table 37 : North American Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, Through 2028
• Table 38 : European Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, Through 2028
• Table 39 : Asia-Pacific Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, Through 2028
• Table 40 : List of Marketed Products Used in Different Nanotechnology-based Techniques
• Table 41 : Major Players in Nanoparticle Drug Development and Formulation Market
• Table 42 : Company Pipeline for Cardiovascular Nanoparticle Drugs
• Table 43 : Company Pipeline for CNS Disease Nanoparticle Drugs
• Table 44 : Company Pipeline for GI Disease Nanoparticle Drugs
• Table 45 : Company Pipeline for Infectious Disease Nanoparticle Drugs
• Table 46 : Company Pipeline for Cancer Nanoparticle Drugs
• Table 47 : Company Pipeline for Ophthalmic Nanoparticle Drugs
• Table 48 : Company Pipeline for Autoimmune Disease Nanoparticle Drugs
• Table 49 : Global Nanotechnology Patents, by Country, 2020-2023
• Table 50 : Bristol-Myers Squibb Co.: Financials, 2020-2022
• Table 51 : Camurus: Financials, 2020-2022
• Table 52 : Camurus: Developments, 2020-2022
• Table 53 : Cytimmune Sciences: Developments, 2020-2022
• Table 54 : Gilead Sciences Inc.: Financials, 2020-2022
• Table 55 : Gilead Sciences Inc.: Developments, 2020-2022
• Table 56 : GlaxoSmithKline PLC: Financials, 2020-2022
• Table 57 : GlaxoSmithKline PLC: Developments, 2020-2022
• Table 58 : Hoffmann-La Roche Inc.: Financials, 2020-2022
• Table 59 : Merck & Co. Inc.: Financials, 2020-2022
• Table 60 : Merck & Co. Inc.: Developments, 2020-2022
• Table 61 : NanoCarrier Co., Ltd.: Financials, 2020-2022
• Table 62 : NanoCarrier Co., Ltd.: Developments, 2020-2022
• Table 63 : Novartis AG: Financials, 2020-2022

List of Figures

• Summary Figure A : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Application, 2020-2028
• Summary Figure B : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Technology, 2020-2028
• Figure 1 : PESTEL Analysis: Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems Market
• Figure 2 : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, 2020-2028
• Figure 3 : Global Market Shares for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, 2023
• Figure 4 : North American Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, 2020-2028
• Figure 5 : North American Market Shares of Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, 2023
• Figure 6 : European Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, 2020-2028
• Figure 7 : European Market Shares of Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, 2023
• Figure 8 : Asia-Pacific Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, 2020-2028
• Figure 9 : Asia-Pacific Market Shares of Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, 2023
• Figure 10 : South American Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, 2020-2028
• Figure 11 : Middle Eastern and African Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, 2020-2028
• Figure 12 : Bristol-Myers Squibb Co.: Research and Development Expenses, 2020-2022
• Figure 13 : Bristol-Myers Squibb Co.: Revenue Share, by Region, 2021
• Figure 14 : Camurus: Research and Development Expenses, 2020-2022
• Figure 15 : Camurus: Revenue Share, by Region, 2022
• Figure 16 : Camurus: SWOT Analysis
• Figure 17 : Gilead Sciences Inc.: Research and Development Expenses, 2020-2022
• Figure 18 : Gilead Sciences Inc.: Revenue Share, by Product Sales, 2022
• Figure 19 : GlaxoSmithKline PLC: Research and Development Expenses, 2020-2022
• Figure 20 : GlaxoSmithKline PLC: Revenue Share, by Segment, 2021
• Figure 21 : GlaxoSmithKline PLC: SWOT Analysis
• Figure 22 : Hoffman-La Roche Inc.: Research and Development Expenses, 2020-2022
• Figure 23 : Hoffman-La Roche Inc.: Revenue Share, by Segment, 2022
• Figure 24 : Merck & Co. Inc.: Research and Development Expenses, 2020-2022
• Figure 25 : Merck & Co. Inc.: Revenue Share, by Segment, 2022
• Figure 26 : Merck & Co. Inc.: SWOT Analysis
• Figure 27 : NanoCarrier Co., Ltd.: Net Assets, 2020-2022
• Figure 28 : Novartis AG: Operating Income, 2020-2022
• Figure 29 : Novartis AG: Revenue Share, by Segment, 2022
• Figure 30 : Novartis AG: SWOT Analysis